Semaglutide reduces heart attack risk by 20%
The Guardian — May 14, 2024, 01:00 AM UTC
Summary: A study presented at the European Congress of Obesity revealed that the weight loss injection semaglutide reduced the risk of heart attacks by 20%. The medication could benefit millions of adults in the UK, regardless of starting weight. Semaglutide is considered a gamechanger in cardiovascular health and could be widely prescribed. Another study showed participants lost 10.2% body weight with semaglutide. Retatrutide, a new slimming jab, led to 24% weight loss in a trial.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.